Neuropilin signalling in angiogenesis
2012 (English)In: Biochemical Society Transactions, ISSN 0300-5127, E-ISSN 1470-8752, Vol. 40, 20-25 p.Article in journal (Refereed) Published
VEGFs (vascular endothelial growth factors) are master regulators of vascular development and of blood and lymphatic vessel function during health and disease in adults. This family of five mammalian ligands acts through three RTKs (receptor tyrosine kinases). In addition, co-receptors such as NRPs (neuropilins) associate with the ligand-receptor signalling complex and modulate the output. Therapeutics to block several of the VEGF signalling components as well as NRP function have been developed with the aim of halting blood vessel formation, angiogenesis, in diseases that involve tissue growth and inflammation, such as cancer. The present review outlines the current understanding of NRPs in relation to blood and lymphatic vessel biology.
Place, publisher, year, edition, pages
2012. Vol. 40, 20-25 p.
angiogenesis, anti-VEGF therapy, biomarker, neuropilin, receptor tyrosine kinase (RTK), vascular endothelial growth factor (VEGF)
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-171682DOI: 10.1042/BST20110689ISI: 000300136600005OAI: oai:DiVA.org:uu-171682DiVA: diva2:512091